Study summary

Pembrolizumab with weekly paclitaxel extended survival

KEYNOTE-B96 trial · Phase 3, double-blind · Published April 2026, The Lancet

17.7 momedian survival with pembrolizumab, vs 14.0

What was tested

Pembrolizumab plus weekly paclitaxel (with or without bevacizumab), against placebo plus paclitaxel, for platinum-resistant recurrent ovarian cancer.

What they found

Median survival was 17.7 vs 14.0 months in the overall population.
Time before growth was also longer.

What it means

The first immunotherapy to extend survival in ovarian cancer.

Lancet, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.